sing interferon to treat COVID-19

Phase 2

Recruiting

• Conditions: COVID-19.; the code for the confirmed diagnosis of COVID-19; RA01.0.

• Registration Number: IRCT20161206031256N3
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Adult over 18 years
Clinical diagnosis of COVID-19

Exclusion Criteria

History of allergy to human albumin or interferon

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body temperature. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Thermometer, Celsius.;Respiratory rate. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Pulse oximeter, Breaths per minute.;The ratio of arterial oxygen partial pressure to fractional inspired oxygen. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Ventilator, Millimeter of mercury (mmHg).;Blood gas level. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Blood Gas Analyzer, percent.